Publisher's note: This series was paid for by National Minority Quality Forum. The views expressed are the authors' own. The National Minority Quality Forum (NMQF) has commissioned this analysis ...
When Medicare coverage for a drug, device, or other medical technology is conditioned on additional evidence development, several important policy questions arise: What will be the utility of the ...
CMS has proposed Medicare and Medicaid coverage for transcatheter tricuspid transcatheter edge-to-edge repair procedures for the treatment of symptomatic tricuspid regurgitation. The procedures would ...
The U.S. Centers for Medicare & Medicaid Services (CMS) has issued a draft coverage memo for cardiac contractility modulation (CCM), which offers coverage with evidence development for the company’s ...
The final U.S. Medicare national coverage determination for transcatheter tricuspid valve replacement (TTVR) devices comes with an expected coverage with evidence development mandate, but some ...
In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results